GH and fatty liver: what the randomized trial actually measured

Less liver fat is the finding to preserve

A randomized trial found that daily injected growth hormone reduced liver fat over six months in adults with overweight or obesity and nonalcoholic fatty liver disease, using the terminology in the 2023 publication. That is a meaningful research result. It does not establish that compounded sermorelin treats fatty liver or prevents liver failure. The study enrolled 53 adults without diabetes and measured liver fat using magnetic resonance spectroscopy. ^[1]

The distinction matters when a hormone-service advertisement moves from abdominal fat to liver health in a single paragraph. A measurable tissue change may identify a promising therapeutic question, but the actual medicine, selected population and endpoint remain attached to the evidence. They do not disappear because related products influence the same broad hormonal pathway.

The study deliberately selected its population

Participants were aged 18 to 65 years, had a BMI of at least 25 and had fatty liver without diabetes. Twenty-seven were assigned GH and twenty-six placebo; forty-one completed six months. The intervention targeted IGF-1 into the upper normal quartile. ^[1] This was a controlled experiment with a defined selection and target, not an evaluation of an unrestricted longevity subscription.

The absence of diabetes is particularly relevant to transfer. A reader whose fatty liver occurs alongside diabetes is not simply another interchangeable example of the enrolled population. The finding may still inform a clinician's understanding of the pathway, but it cannot by itself establish that the same balance of benefit and risk applies. Eligibility criteria describe the boundary of the evidence rather than a universal list of people who should seek this treatment.

For the broader metabolic question, read sermorelin and glucose evidence.

The effect was measured in liver-fat percentage

Liver-fat change averaged minus 5.2 percentage points with GH and plus 3.8 with placebo. The estimated net difference was minus 8.9 percentage points, with a 95% confidence interval from minus 14.5 to minus 3.3. ^[1] These are changes in an imaging-based fat measure, not an 8.9% reduction in every liver-related clinical risk.

The units matter. A percentage-point difference in a tissue measure cannot be swapped for a relative reduction in cirrhosis, hospitalization or death. The confidence interval describes uncertainty around the measured treatment comparison. It does not turn the result into an individual forecast, and it does not tell a patient how much of an apparent improvement would be necessary to change their own clinical management.

Fat, inflammation and scarring are different questions

NIDDK distinguishes tests for liver fat from assessment of inflammation and fibrosis. Its patient information explains that routine imaging can show fat, while other evaluation may be needed to characterize more advanced disease; elastography assesses stiffness, and biopsy can establish steatohepatitis and characterize tissue injury. ^[2] The older labels NAFLD and NASH now often appear alongside MASLD and MASH.

For this trial, the important reading habit is to keep the stated primary endpoint intact. A favorable fat measurement should not be presented as proof that all features of liver disease resolved. A consumer does not need to master every diagnostic method to recognize that a scan, a liver-enzyme value and a biopsy conclusion answer different questions. A credible explanation identifies which result was actually demonstrated.

Tolerability included an edema signal

Lower-extremity edema was reported more often with GH, at 21% versus none with placebo. The investigators found no significant between-group differences in changes in glycemic measures or insulin resistance, and no discontinuations for worsening glycemic status. ^[1] Those observations are relevant to the enrolled sample and six-month window.

They should not become a blanket claim that GH is metabolically harmless. Small studies have limited ability to describe uncommon problems, and a selected group without diabetes cannot settle every concern in a broader metabolic population. Our assessment is that a fair interpretation should give the liver-fat result credit while keeping the adverse-event finding visible. Selecting only the favorable metabolic comparison would produce a less useful account of the actual experiment.

This was GH, not a sermorelin service trial

The administered intervention was daily subcutaneous GH. ^[1] A sermorelin service offers a different molecule and clinical arrangement. There was no randomized comparison with sermorelin here, and no evidence in this trial about a particular telehealth provider's preparation, pharmacy, follow-up or purchase terms.

That gap cannot be filled by saying that both affect IGF-1. Shared downstream biology is a reason to formulate a research hypothesis; it does not establish equal effects or equal risks. A patient comparing a service should therefore ask for the evidence relevant to the actual proposed medicine and clinical purpose. A favorable review of convenience or billing would not answer the liver-treatment question and should not be presented as if it did.

A different analogue and population are examined in tesamorelin and liver fat in HIV.

A clinical diagnosis still comes before a hormone claim

Endocrine Society guidance on adult GH deficiency emphasizes diagnostic assessment, the limits of IGF-1 alone and individualized treatment decisions. It describes the greatest expected benefit in people with more severe deficiency. ^[3] That framework should not be replaced by a retailer's interpretation of a low-normal number or a general desire to improve body composition.

NIDDK similarly describes fatty-liver diagnosis as a combination of history, examination and appropriate tests, including consideration of other causes. ^[2] A liver result belongs with the clinician managing the underlying condition. Purchasing a hormone panel or seeing a promising study does not establish a diagnosis, select the right medicine or create an ongoing monitoring plan. Those are clinical decisions that the publication cannot make for the reader.

For the diagnostic distinction, see our GH diagnostic testing guide.

What the result can usefully contribute

The study supports further investigation of the GH–IGF-1 pathway in selected fatty-liver populations. It provides a concrete imaging result and a reason to ask better questions about longer-term outcomes, more diverse clinical groups and the tradeoff between benefit and adverse effects. That is a substantive contribution without a broader treatment endorsement.

For a consumer assessing a hormone service, the practical conclusion is to preserve the boundary: this was a defined GH experiment in people without diabetes, not evidence that sermorelin subscriptions treat MASLD. Compare an actual care agreement on its own purpose and responsibilities, and evaluate any liver-health claim against the medicine and outcome that were studied. The research becomes more informative when its limits stay visible.